An interventional study of Group I (WhatsApp) motivational and educational messages delivered periodically and Group II: To implement the SMART method in Diabetes Mellitus, Type 2/Prevention & Control, Diabete Type 2 and Treatment Adherence, sponsored by Instituto Mexicano del Seguro Social. Completed at 1 site in Mexico. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Instituto Mexicano del Seguro Social · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 451 studies in Diabetes Mellitus, Type 2 with a site in Mexico — 27 open to participants now, 43 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Mexico.
Among the 451 studies in Diabetes Mellitus, Type 2 with a site in Mexico, this one is the 294th largest by enrollment of the 427 interventional ones that give a count, is one of 13 that started in 2024, is one of 43 with no phase, and was the 449th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →27 of the 451 studies in Diabetes Mellitus, Type 2 with a site in Mexico are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Mexico, United States, Argentina and 13 more countries
Ages 45+
Novo Nordisk A/S · Sites in Mexico, United States, Argentina and 7 more countries
Ages 10–18
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Sites in Mexico
Ages 18+
Eli Lilly and Company · Sites in Mexico, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Mexico, United States, Argentina and 21 more countries
Ages 18+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
451 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 70 · Phase 3 269 · Phase 4 43
First in 2000; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 442 across the 427 interventional studies, 1,000 across the 23 observational. Of the 383 that completed or were terminated, 240 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
372 of 451 have an industry lead sponsor. The 10 most frequent:
Instituto Mexicano del Seguro Social is the lead sponsor of 126 studies on the registry; 21 are open to participants now.
Instituto Mexicano del Seguro Social has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
7 of the studies in Diabetes Mellitus, Type 2 with a site in Mexico that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07628985Phase 3Carnot LaboratoriesBALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes | 2027-10 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT07401992Hospital Universitario Dr. Jose E. GonzalezEffects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | 2027-02-28 |
| NCT06069518Coordinación de Investigación en Salud, MexicoContinuous Glucose Monitoring in Patients With Diabetes on Peritoneal Dialysis | 2027-03-31 |
| NCT06163248Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranChrono Nutrition and Insulin Resistance in Diabetes | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 451 studies in Diabetes Mellitus, Type 2 with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A quasi-experimental, non-randomized, prospective, longitudinal study comparing the use of WhatsApp messaging versus the SMART technique in patients with type 2 diabetes to improve treatment adherence
The study included patients with type 2 diabetes who received training on diabetes, lifestyle, and self-management prior to the implementation of reinforcement messages or the use of the SMART technique at a primary care facility in Mexico.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 250 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Instituto Mexicano del Seguro Social is the lead sponsor of 126 studies on the registry; 21 are open to participants now.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria:
Patients with type 2 diabetes mellitus.
Exclusion Criteria:
Patients with type 1 diabetes mellitus.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group I: Participants received behavioral training and education on T2D, treatment adherence, and polypharmacy, along with the messages shown below via WhatsApp. Positive reinforcement messages were sent once every two days for two weeks, followed by one per week for three weeks.
Other: Group I (WhatsApp) motivational and educational messages delivered periodically
Group II: To implement the SMART method, the patient was first given an explanation of the concept of a goal or objective, as well as what each of the concepts of the SMART method entails. The participant was then asked to identify a goal that meets the SMART criteria and, above all, is measurable.
Other: Group II: To implement the SMART method
Positive reinforcement messages were sent once every two days for two weeks, then once a week for three weeks
Group II: To implement the SMART method, the patient was first given an explanation of the concept of a goal or objective, as well as what each of the concepts of the SMART method entails. The participant was then asked to identify a goal that meets the SMART criteria and, above all, is measurable.
Therapeutic adherence
According to the Morisky-Green questionnaire: Good \>8 points, Fair 6-7 points, Poor \<6 points
Time frame: Assessments were conducted at the start of the study "Baseline" (November to December 2024) and "6 months" after the intervention (May to June 2025)
multipharmacy
Patients will be divided into two groups based on the START/STOP criteria: Positive \> 6 medications Negative \< 5 medications A list of the medications taken by the patients will be compiled.
Time frame: Evaluations were conducted at the start of the study "Baseline" (November to December 2024).
Glucose
Glucose: This information will be obtained from laboratory results in the medical record. According to the ADA: 80-130 mg/dl: controlled \>130 mg/dl: uncontrolled
Time frame: Assessments were conducted at the start of the study "Baseline" (November to December 2024) and "6 months" after the intervention (May to June 2025).
Cholesterol
Total cholesterol; This will be derived from laboratory results obtained from the medical record. 1. Optimal \<185 mg/dl 2. High \>186 mg/dl
Time frame: Assessments were conducted at the start of the study "Baseline" (November to December 2024) and "6 months" after the intervention (May to June 2025).
Triglycerides
These values will be obtained from laboratory results in the medical record. According to the ADA: Controlled: \<150 mg/dl Uncontrolled: \>151 mg/dl
Time frame: Assessments were conducted at the start of the study "Baseline" (November to December 2024) and "6 months" after the intervention (May to June 2025).
Body Mass Index:
The Body Mass Index is calculated as body weight divided by height squared (kg/m²). 1. Underweight \<18.5 kg/m² 2. Normal: 18.5-24.9 kg/m² 3. Overweight: 25-29.9 kg/m² 4. Class I obesity: 30-34.9 kg/m² 5. Class II obesity: 35-39.9 kg/m² 6. Class III obesity: \>40 kg/m²
Time frame: Assessments were conducted at the start of the study "Baseline" (November to December 2024) and "6 months" after the intervention (May to June 2025).
Knowledge of type 2 diabetes
Using the DKQ-24 questionnaire, is assessed as follows: Answers are marked as correct or incorrect, and a percentage is assigned based on the number of correct answers. A score of 80% or higher indicates good knowledge. \> 19: Knowledge \< 19: Lack of knowledge
Time frame: The questionnaire was administered at the start of the study "Baseline" and at the end of the course on the basics of type 2 diabetes, "After a week" during the recruitment period from November to December 2024.
Plan to share: No — The data was collected by Dr. Raúl Jaimes Salgado, who assigned a code to each patient. The data will be recorded on a data collection form and entered into an Excel spreadsheet with the assistance of Drs. María Magdalena Valencia Gutiérrez and María del Pilar Rodríguez. María Magdalena Valencia will then analyze the data.
Ran from Nov 2024 to primary completion in Dec 2025, 13 months.
Of 2,068 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 13 months is below that.
Counting every sponsor, half of 2,245 studies reached it within 21 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Mexicano del Seguro Social →